Business Wire

Excelya Welcomes Three European Contract Research Organizations to Become One Stop Provider Throughout Europe

Share

Today, Excelya, a leading contract research organization (CRO) specializing in clinical research, announced that three European CROs joined Excelya Group: Zeincro based in Central-Eastern & Southern Europe, The Clinical Company based in the Netherlands and Belgium and Koehler eClinical based in Germany. Together, they will be known as Excelya Group. This alliance will allow Excelya to offer a one stop provider service model throughout Europe for its clients, whether they need full service, functional service providing or consulting services.

Zeincro is a leading contract research organization primarily operating in Central-Eastern & Southern Europe with particular expertise in clinical operations, safety and medical affairs. The Clinical Company is present in the Belgian and Dutch markets specializing in clinical operations. Koehler eClinical is a German specialty CRO with a focus on biostatistics and data solutions. Thanks to the unification with these three companies, Excelya Group is now a leading European full service CRO providing services in 24 European countries. Excelya Group now employs 800 people in six areas of expertise, with expected combined revenues of €70 million in 2020.

Francois Moisson, CEO at Excelya: “Our newly European scale and reach will allow us to provide a full suite of end-to-end clinical solutions for our clients where they need them. These investments in innovation and delivery capacity position us to rapidly continue our growth in the short and medium term.”

About Excelya Group

Excelya is an independent European contract research organization with over 800 employees, 17 offices and 12 legal entities spread throughout Europe. Excelya offers all cooperation models, from consulting to functional service providing to full-service. It provides these research services across multiple industries, including pharmaceutical, biotech, medical devices, cosmetics and nutrition. As a fully integrated CRO, Excelya undertakes the design and execution of Phase I clinical trials to post-marketing studies, safety, biometrics and market access projects. Excelya is committed to providing preeminent experts who work hand-in-hand with its clients to accelerate end-to-end drug development, leverage data science and reimagine patient care.

For more information, please visit excelya.com.

About Zeincro

Zeincro is a CRO created in 1999 headquartered in the United Kingdom that provides services to more than 20 countries in Central-Eastern & Southern Europe through eight offices. Zeincro provides a full range of services from Phases I to IV with a specialization in clinical operations and safety across most therapeutic areas. With almost 20 years of experience in more than 700 successful clinical studies completed, Zeincro has developed a thorough understanding of the communities and the regions in which it operates. This approach allows ZEINCRO to set new standards for successful clinical trials by delivering bespoke services that maximize patient recruitment and compliance.

For more information, please visit zeincro.com.

About Koehler eClinical GmbH

Koehler eClinical GmbH is a mid-size specialty CRO with more than 25 years of experience in providing value-added services for its customers. With its strong heritage in biostatistics, it covers all study phases as well as biostatistical and regulatory consulting, meta-analyses, data integration and standardizations. As a specialist in data-centric approaches, the company also operates its proprietary software VITESSA as a combined tool for electronic data capture and clinical trial management. Koehler eClinical GmbH provides full-service support for local and global trials with centralized project management and technology-enabled approaches. It covers the full spectrum of clinical projects, from early to late-phase, including NIS, observational and PASS.

For more information, please visit koehler-eclinical.com.

About The Clinical Company

Founded in 2002, The Clinical Company is based in Amstelveen, The Netherlands and Leuven, near Brussels, Belgium. The Clinical Company specializes in delivering clinical services in the Benelux to their (Bio)Pharmaceutical, Medical Device and CRO Clients. The Clinical Company is a full service CRO that provides services from Phases I to IV in all major therapeutic areas and conducts clinical trials in eight countries in Western Europe.

For more information, please visit theclinicalcompany.com.

Project Contributors:

  • Excelya: François Moisson & Frédéric Paqueville (CEO & Co-Founders), Guillaume Steimer
  • Legal counsel:
    • FieldFisher: Philippe Netto, Hélène Lefebvre, Antoine Gabizon (Fr), Mark Walker (UK), Louis Bouchez and Jan Schouten (NL), Florian Streiber (D), Louis-Francois du Castillon (Bel) ;
    • De Pardieu Brocas Maffei: Philippe Rozec
  • Financial Audit: Oderis, Aurélien Vion
  • Financing: Banking pool (SG,LCL, CIC, HSBC), leading agent: Société Générale, Erkan Suer,
  • Zeincro: Dr Gregory Sivolapenko,
  • Koehler eClinical: Dr Manfred Koehler, Dr Antal Hajos, Michael Pfitzenmaier,
  • The Clinical Company: Pim Van de Riet, Chris de Jong, Evert Cuppens, Stijn Valkering, Angélique Kleemans
  • Legal and financial advisors:
    • Zeincro: CMS Cameron McKenna Nabarro Olswang LLP, John Finnemore
    • The Clinical Company: CMS Derks Star Busmann N.V, Pieter van Duijvenvoorde, & Breezeholme Advisory Services, Pim van de Riet
    • Koehler eClinical: Dr. Reinhard Hermes, & VALNES Corporate Finance GmbH, Michael Graser

Contact information

Guillaume Steimer, Strategic Development Director
gsteimer@excelya.com / +33 6 07 05 51 36

Amélie Janson, Communications Director
ajanson@excelya.com / +33 6 47 87 31 41

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pacific Drilling Commences Voluntary Chapter 11 Proceedings; Restructuring Support Agreement to Eliminate All $1.1 Billion of Bond Debt; World-wide Operations Expected to Continue as Usual31.10.2020 00:52:00 CETPress release

Pacific Drilling S.A. (NYSE: PACD) announced today that it and certain of its domestic and international subsidiaries have filed voluntary petitions for relief under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the Southern District of Texas and have entered into a restructuring support agreement with an ad hoc group of the largest holders of its outstanding bond debt. This consensual financial restructuring transaction will eliminate the Company’s approximately $1.1 billion in principal amount of outstanding bond debt through the cancellation and exchange of debt for new equity in the reorganized Company. The Company also announced today that it has repaid its $50 million first lien superpriority revolving credit agreement with Angelo, Gordon Energy Servicer, LLC, as administrative agent and the lenders party thereto. With approximately $120 million of cash and cash equivalents as of October 30, 2020, and seven of the most advanced high-spe

Homestead Capital Closes Fund III at Target, Surpasses $1 Billion in Cumulative AUM31.10.2020 00:07:00 CETPress release

Homestead Capital USA LLC (“Homestead”), a private equity firm investing in farmland in the United States, has held a final close of its third fund, Homestead Capital USA Farmland Fund III, L.P. (“Fund III”), with $596 million in capital commitments. With these additional commitments, the firm has surpassed $1 Billion in AUM across its three funds. “We are grateful for the support and opportunity to invest on behalf of our broad range of returning and new investors,” said Dan Little, Co-Founder and Co-CEO of Homestead. “We are humbled by our limited partners’ confidence in us as investors. Fund III represents an endorsement of our ability to drive positive investment outcomes and act as long-term stewards of our limited partners’ capital.” “The United States farmland market continues to undergo a transition that presents many attractive investment opportunities,” said Gabe Santos, also a Co-Founder and Co-CEO of Homestead. “Our strategy is uniquely suited to create value by utilizing o

Bennett Goodman and Avi Kalichstein Launch Hunter Point Capital to Invest in Alternative Investment Managers30.10.2020 19:03:00 CETPress release

Bennett Goodman and Avi Kalichstein today announced the formation of Hunter Point Capital LP (“HPC”), an independent investment firm seeking minority stakes in middle-market alternative asset managers. As part of the launch, HPC has formed a strategic partnership with a group of leading global investment entities associated with Jacob Rothschild. "I am thrilled to initiate this next phase of my career with such an exceptional team. Our HPC partnership seeks to leverage our collective expertise as investors and business builders to cultivate the next generation of outstanding investment franchises,” said Goodman. “Our goal is to help general partners achieve their long-term business objectives faster and with more certainty.” “At our core, Hunter Point Capital is focused on investment excellence. We seek managers with proven track records, who will benefit from a strategic, impact-oriented partner,” said Kalichstein. “There is an expanding universe of high-performing investment manageme

Code:n@xt: PROCAD to Lift the Veil on a New PLM Generation30.10.2020 17:31:00 CETPress release

On November 11, 2020, PRO.FILE next, the next product generation by PROCAD will be officially launched. At 11:00 AM EST, 10:00 AM CET, the groundbreaking, cloud-enabled platform for the digital transformation of business processes will be presented to the public for the first time at Code:n@xt, a must-attend event for anyone interested in digital transformation, information and product lifecycle management. PROCAD's managing directors, strategists, business developers, and developers will come together for Code:n@xt to present PRO.FILE next – whose code will change the world of PLM software. The online event will feature breakout sessions and a live demo of the new system, take a look at today's market demands and digital transformation trends, and give attendees the opportunity to chat with the company's experts. Where does digital transformation start? Where does a PLM platform as a Product Data Backbone fit into it? How do you build an information twin as a digital replica of a piec

INX Applies for Listing on the Canadian Securities Exchange (CSE)30.10.2020 14:00:00 CETPress release

INX Limited (“INX”) today announced its application for listing of its digital security, the INX Token, on the Canadian Securities Exchange (“CSE”). The listing application is subject to the approval of the CSE. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201030005313/en/ Shy Datika, Co-Founder and President at INX (Photo: Business Wire) INX recently launched the first SEC-registered digital security IPO for both retail and institutional investors. INX intends to use the net proceeds from the IPO for a launch of a regulated trading platform for digital assets and provide novel trading and capital raising financial instruments to enterprises in collaboration with traditional exchanges worldwide. The CSE is a proponent of exchange-listed digital securities and continues to work towards additional services in connection with the post-trade processes for these securities. Richard Carleton, CEO of the CSE has stated that “The

Veracyte Announces New Data Published in Journal of Clinical Oncology Suggest the Prosigna Breast Cancer Test’s Genomic Underpinning Drives Prognostic Performance30.10.2020 13:15:00 CETPress release

Veracyte, Inc., (Nasdaq: VCYT) announced today that findings from the first study evaluating the molecular drivers underlying multiple prognostic genomic breast cancer tests were published in the Journal of Clinical Oncology (JCO). Results suggest that the genomic underpinnings of Veracyte’s Prosigna® Breast Cancer Gene Signature Assay, particularly the test’s relative weighting of genes predicting tumor proliferation, may explain the classifier’s previously demonstrated, higher likelihood of predicting long-term risk of recurrence among certain breast cancer patients, compared to other breast cancer tests. The study compared the commercial forms of four breast cancer recurrence-risk tests: the PAM50-based Prosigna Risk of Recurrence (ROR), the Oncotype DX Risk Score (RS), EndoPredict (EP) and Breast Cancer Index (BCI). It expands upon a previous evaluation of these same tests using an identical dataset, which compared their ability to accurately predict 10-year distant disease recurre

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom